About Aivita Health Group

Health is not about repair—it's about foresight. We are engineering a comprehensive health ecosystem that keeps people ahead of disease instead of reacting to it.

Brand Story & Mission

From Treatment to Foresight

Aivita Health Group was founded on a simple but radical belief: health should not begin at the point of crisis. Health is not about repair—it's about foresight. Instead of waiting for disease to appear, we focus on predicting risks, preserving function, and extending the years in which people can truly live well.

Our roots span regenerative medicine, biotechnology, and human-centered design. Rather than building just another clinic, we are creating a connected ecosystem that links advanced diagnostics, cellular therapies, AI-supported decision tools, and lifestyle programs into one coherent experience.

Aivita exists to bridge the gap between frontier science and everyday life—turning complex cellular innovation into accessible, meaningful care for individuals, families, and communities.

Our Mission in Action

🧬

Cellular Regeneration

Applying stem cells, exosomes, and iPSC-based technologies to repair, rejuvenate, and protect tissues before irreversible damage occurs.

🤖

AI & Data Intelligence

Building AI-supported health databases and decision tools that help clinicians see patterns earlier, personalise care, and move from reactive treatment to proactive management.

🩺

Personalised Preventive Medicine

Designing programs based on biological age, functional status, and risk profiling—so that prevention becomes precise, measurable, and trackable over time.

🌱

Everyday Lifestyle & Movement

Extending our philosophy beyond the clinic into nutrition, movement therapy, and living environments, ensuring that "treatment" is woven into daily life, not limited to hospital visits.

Our Roadmap to 2030

Aivita Health Group is intentionally built in stages. We are investing first in science, platforms, and ecosystem design—so that when we scale, we do so with quality, safety, and long-term value at the core.

2024–2025
Foundation Phase

Establishing our flagship clinic in Dubai, core laboratory partnerships, and platform architecture. This is a deliberate pre-revenue phase focused on infrastructure, protocols, and regulatory pathways.

2026
Market Entry

Launching clinical services, selected products, and wellness programs under the Aivita umbrella. Initial commercialisation with disciplined, data-driven growth in key markets.

2027–2028
Scale & Expansion

Expanding our clinic network, retreat destinations, and lifestyle brands, while deepening our technology stack across regenerative medicine, AI health tools, and cellular platforms.

2029–2030
Pre-IPO & Beyond

Consolidating our ecosystem into a mature, scalable health platform with global visibility, preparing for an IPO and long-term value creation for patients, partners, and investors.

Core Values

🔬

Scientific Excellence

We are committed to the highest standards of scientific rigor and evidence-based medicine. Every solution we develop is grounded in solid research and clinical validation.

🤝

Collaborative Innovation

We believe that breakthrough innovations emerge from collaborative efforts. We foster partnerships with leading researchers, clinicians, and technology pioneers worldwide.

👥

Patient-Centered Care

Our patients are at the heart of everything we do. We are dedicated to providing personalized, compassionate care that addresses individual needs and preferences.

🌍

Global Impact

We strive to make advanced healthcare accessible globally, breaking down barriers and ensuring that innovative treatments reach those who need them most.

Continuous Innovation

We embrace change and continuously seek new ways to improve healthcare outcomes through technology, research, and innovative approaches.

Integrity & Trust

We operate with the highest levels of integrity, transparency, and ethical standards, building trust with patients, partners, and communities.

Leadership Team

Leadership

Chairman Hussain Sultan

Hussain Sultan

Chairman

CEO Cynthia Hung

Cynthia Hung

CEO

Executive Team

CTO HUNG,YING-CHENG

HUNG,YING-CHENG

CTO

Dr. CHANG,YU-FEN

Dr. CHANG,YU-FEN

Consultant
Dr. CHUNG,MIN-WEN

Dr. CHUNG,MIN-WEN

Consultant
CEO Pei-Xiang Yan

Pei-Xiang Yan

Consultant

Strategic Partners

We collaborate with leading biotechnology companies and research institutions to bring the most advanced healthcare solutions to our patients.

Axel Biotechnology Inc.

Taiwan

Axel Biotechnology Inc. specializes in evaluating the effectiveness and purity of small biological particles used in advanced treatments. Their technology helps ensure that these products are clean, active, and suitable for use in health therapies. By checking size, origin, safety, and activity, Axel provides clear and trustworthy information for professionals developing next-generation solutions in wellness and recovery.

Quality Testing Health Innovation Therapeutic Safety

LumiSTAR Biotechnology Inc.

Taiwan

LumiSTAR Biotechnology focuses on developing research pipelines based on pluripotent stem cell technology and has introduced a real-time cellular detection system, LumiRDT, which uses gene-edited fluorescent reagents to accurately monitor cell function. These tools are designed for high-throughput screening, drug development, and cellular function research—enhancing the speed and reliability of regenerative medicine and precision treatment innovations.

iPSC-Based Therapeutics Real-Time Cell Detection High-Throughput Screening